Autoimmunity News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

Diabetes researcher awarded 2013 JDRF Australia Lifetime Research Achievement Award

Diabetes researcher Professor Len Harrison has been awarded the 2013 JDRF Australia Lifetime Research Achievement Award for his research to improve treatments for people with diabetes, or prevent its development.

11 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

Cocktail eradicates animals' brain tumors

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

26 Nov 2013

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.

18 Nov 2013

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Northwestern Medicine- scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

12 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Researchers have linked a species of intestinal bacteria known as Prevotella copri to the onset of rheumatoid arthritis, the first demonstration in humans that the chronic inflammatory joint disease may be mediated in part by specific intestinal bacteria.

6 Nov 2013

Astrazeneca, Evotec Launch Kidney Disease Collaboration

...

21 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Astrazeneca Acquires Spirogen For Up To $440M

...

15 Oct 2013

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

A National autoimmune disease multi-city conference tour arrives in Charleston, SC on Saturday, November 2, 2013. The conference "What Every American Needs to Know About Autoimmune Disease," is one of a series of free patient forums hosted by the American Autoimmune Related Diseases Association.

15 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI).

7 Oct 2013

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show.

27 Sep 2013